With the recent FDA approval of Grass and Ragweed, many patients are asking if other allergern will be available soon.
Most allergic patients do not have only grass and ragweed allergies, but many others including trees, molds, cats, dogs and dust mite. Dust mite is one of the most common allergens people suffer from and it was one of the most unavoidable as well. A recent study investigated dust mite sublingual immunotherapy and to see if it worked.
Over 500 participants were recruited who had dust mite allergic rhinitis and were randomized to 3 groups, placebo, low dose dust mite, and higher dose dust mite. They were studied for over a year.
Both the low and higher dose sublingual tablets significantly reduced average symptoms compared to placebo. The onset of action was at 4 months. Adverse events were minimal.
We will most likely see dust mite sublingual tablets in the eventual future as the studies are showing its efficacy. What would be most interesting it to compare dust mite sublingual versus subcutaneous immunotherapy.